Paradox Immunotherapeutics Secures $10 Million Investment from SymBiosis

Big news for the biotech scene—Paradox Immunotherapeutics, a Toronto-based H2i venture that is pioneering antibody therapies for protein misfolding diseases, recently announced a $10 million investment from SymBiosis Capital Management to accelerate its drug development pipeline.

Paradox is laser-focused on treating immunoglobulin light chain (AL) amyloidosis—a complication of multiple myeloma that wreaks havoc on vital organs—and leukocyte chemotactic factor 2 (LECT2) amyloidosis, an under-the-radar but serious driver of chronic kidney disease. Their approach? A next-gen antibody platform that selectively targets misfolded proteins while leaving healthy ones untouched—something that’s notoriously difficult in drug development.

“This investment is a major validation of our science and its potential impact,” said Dr. Natalie Galant, Co-Founder & CEO of Paradox Immunotherapeutics. “There’s an enormous unmet need in amyloidosis treatment, and SymBiosis’ support gives us the fuel to move our pipeline forward at full speed.”

SymBiosis, an investment firm with a sharp eye for breakthrough biotherapeutics, sees massive potential in Paradox’s approach. Chidozie Ugwumba, Managing Partner at SymBiosis, weighed in: “Protein misfolding diseases are complex, but Paradox is building a first-in-class solution with real clinical impact. We’re excited to back this team as they redefine treatment possibilities.”

Alongside the funding, the team announced that industry veteran Sandy Zweifach will be stepping in as Executive Chairman, bringing years of biotech expertise to help Paradox scale.

Paradox has been making waves in the biotech world, earning spots in J.P. Morgan’s Life Sciences Innovation Summit, BIO Emerging Company Start-Up Stadium, and Springboard Enterprises Life Sciences Program—cementing its place as a rising star in the protein misfolding space.

With this new round of funding, Paradox is poised to push its next-gen amyloidosis treatments closer to reality—one step closer to solving some of the most elusive challenges in biotech.

Stay tuned as Paradox continues to make great strides in the fight against protein misfolding diseases…

💡 Read the press release here!